These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6105188)

  • 21. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
    Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
    Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clearance of ingested sucrose solutions from the gastrointestinal tract of the rat: replication report.
    Beck RC
    Psychol Rep; 1969 Jun; 24(3):753-4. PubMed ID: 5809069
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetics of long acting propranolol. Implications for therapeutic use.
    Nace GS; Wood AJ
    Clin Pharmacokinet; 1987 Jul; 13(1):51-64. PubMed ID: 3304770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
    Wagner JG
    Clin Pharmacol Ther; 1985 May; 37(5):481-7. PubMed ID: 3987171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Influence of taurine analogue on the absorption of salicylic acid derivatives in rat gastrointestinal tract].
    Morisaka K; Nakamoto Y
    Yakugaku Zasshi; 1969 Dec; 89(12):1718-23. PubMed ID: 5392861
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
    Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
    Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.
    Byrne AJ; McNeil JJ; Harrison PM; Louis W; Tonkin AM; McLean AJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):45S-50S. PubMed ID: 6743474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of drug release rate on therapeutic outcomes: formulation dependence of gastrointestinal toxicity of diclofenac in the rat.
    Khazaeinia T; Jamali F
    Inflammopharmacology; 2004; 12(1):69-80. PubMed ID: 15035780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absorption and processing of milk-borne prostaglandin in the suckling rat gastrointestinal tract.
    Bedrick AD; Johnson S; Koldovský O
    Endocr Regul; 1991 Jun; 25(1-2):74-8. PubMed ID: 1958837
    [No Abstract]   [Full Text] [Related]  

  • 30. Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers.
    Sörgel F; Naber KG; Jaehde U; Reiter A; Seelmann R; Sigl G
    Am J Med; 1989 Nov; 87(5A):62S-65S. PubMed ID: 2589388
    [No Abstract]   [Full Text] [Related]  

  • 31. Segmental difference in transmucosal fluid movement and glucose effect on drug absorption from rat gastrointestinal tract.
    Kitazawa S; Ito H; Sezaki H
    Chem Pharm Bull (Tokyo); 1977 Jan; 25(1):19-28. PubMed ID: 852082
    [No Abstract]   [Full Text] [Related]  

  • 32. Avoidance of first pass elimination of propranolol after rectal administration to rats.
    de Boer AG; Gubbens-Stibbe JM; Breimer DD
    J Pharm Pharmacol; 1981 Jan; 33(1):50-1. PubMed ID: 6114157
    [No Abstract]   [Full Text] [Related]  

  • 33. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
    Heinzow B; Corbett H; Constantinides S; Bourne R; McLean AJ
    J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alteration in the disposition and metabolism of S(-)-propranolol in rats with active respiratory viral infection.
    Kwong EC; Laganière S; Savitch JL; Nelson WL; Shen DD
    Life Sci; 1988; 42(12):1245-52. PubMed ID: 3347149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.
    Evans GH; Nies AS; Shand DG
    J Pharmacol Exp Ther; 1973 Jul; 186(1):114-22. PubMed ID: 4198771
    [No Abstract]   [Full Text] [Related]  

  • 36. Factors influencing absorption and excretion of drugs. I. Effect of food on gastrointestinal absorption of amobarbital in rats.
    Kojima S
    Chem Pharm Bull (Tokyo); 1973 Nov; 21(11):2432-7. PubMed ID: 4779831
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of an in vitro absorption model system for predicting sustained release of verapamil.
    Neubert R; Fahr F; Mäder C; Lücke L; Fries G; Rostock G
    Arzneimittelforschung; 1992 Sep; 42(9):1098-100. PubMed ID: 1445475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Automatic system for evaluation of the velocity of dissolution rate of solid dosage forms].
    Zecchi V; Cini M; Rodriguez L; Magnani M
    Boll Chim Farm; 1979 Mar; 118(3):168-75. PubMed ID: 475908
    [No Abstract]   [Full Text] [Related]  

  • 40. Gastrointestinal loss of galanthamine hydrobromide in rats in-situ.
    Yamboliev I; Mutafova-Yambolieva V; Mihailova D
    J Pharm Pharmacol; 1993 Aug; 45(8):763-5. PubMed ID: 7901379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.